Journal article Open Access

Not Tripping over TRIPS: An Analysis of Necessity and Legality of the COVID-19 TRIPS Waiver Proposal

Ahan Gadkari; Sofia Dash

Sponsor(s)
Blue Eyes Intelligence Engineering and Sciences Publication (BEIESP)

The availability of vaccinations against COVID-19 provides hope for containing the epidemic, which has already claimed over 2.84 million lives. However, inoculating millions of individuals worldwide would need large vaccine manufacturing followed by fair distribution. A barrier to vaccine development and dissemination is the developers' intellectual property rights. India and South Africa have jointly sought to the World Trade Organization that certain TRIPS rules of COVID-19 vaccines, medicines, and treatments be waived. This piece argues for such a waiver, highlighting the unique circumstances that exist. It believes that TRIPS's flexibilities are inadequate to cope with the present epidemic, particularly for nations without pharmaceutical manufacturing competence.

Files (282.3 kB)
Name Size
E66750110522.pdf
md5:6a2f61cdc792a0551ecef97d92854094
282.3 kB Download
36
19
views
downloads
Views 36
Downloads 19
Data volume 5.4 MB
Unique views 31
Unique downloads 19

Share

Cite as